Clinical trial
Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.
NCT06754553 is registered in ClinicalTrials.gov with University Hospital, Strasbourg, France as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.
- Lead sponsor
- University Hospital, Strasbourg, France
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- February 28, 2025
- Completion date
- February 28, 2026
- Enrollment
- 100 (estimated)
- Sites
- 16
Conditions
As the registry lists them; a condition with its own page is linked.